Developments in the Management of Myelofibrosis After ASH 2024 - Episode 6

Other Notable Myelofibrosis Data From ASH 2024

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.

EP. 1: Treatment Trends: JAK Inhibitor Selection in Myelofibrosis
EP. 2: Challenges With Low-Dose Ruxolitinib in Myelofibrosis
EP. 3: The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis
EP. 4: PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis
EP. 5: Data for Navtemadlin in Relapsed/Refractory Myelofibrosis
Now Viewing
EP. 6: Other Notable Myelofibrosis Data From ASH 2024

Related Content:

Developments in the Management of Myelofibrosis After ASH 2024Sylvester Comprehensive Cancer Center, University of MiamiMyeloproliferative Neoplasms
Data for Navtemadlin in Relapsed/Refractory Myelofibrosis
PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis
The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis